Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024)

Artiva Biotherapeutics (ARTV) reported Revenue of $251000.0 for Q1 2024, down 85.91% quarter-over-quarter from $1.8 million in Q4 2023.

Artiva Biotherapeutics (ARTV) Revenue (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Revenue data on file, last reported at $251000.0 in Q1 2024.

Revenue for Q1 2024 came in at $251000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $251000.0 (changed N/A YoY), and the FY2024 annual result was $251000.0, down 99.24% from the prior year.
Revenue slipped to $251000.0 in Q1 2024 per ARTV's latest filing, from $1.8 million in the prior quarter.
Over five years, Revenue peaked at $26.7 million in Q3 2023 and troughed at $251000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	5.21 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	306.30 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	2.99 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Artiva Biotherapeutics	241.85 Mn	241.85 Mn	-	-

Download Data